Fibroblast growth factor receptor 4
Synonyms: CD334, JTK2
The fibroblast growth factor is a receptor tyrosine kinase signaling pathway that fundamentally regulates embryogenesis, angiogenesis, tissue homeostasis, and wound repair1. Alterations in FGFR signaling are associated with a broad range of congenital craniofacial developmental disorders, and somatic mutations of FGFR also have a role in oncologic evolution. FGFR4 is one of the 4 highly conserved transmembrane tyrosine kinase receptors. FGFR4 forms complex with FGF19, which has unique specificity for it, and upon binding to it, activates different intracellular pathways, including GSK3β/β-catenin/E-cadherin signalling2.
FGFR4 kinase assay is run on mobility shift microfluidics platform (Caliper), which provides best in industry quality of data. We routinely run services associated with this kinase including: screening, profiling, dose-response studies and kinetic measurements. Please contact us for more information.
1. Chae YK, Ranganath K, Hammerman PS, Vaklavas C, Mohindra N, Kalyan A, Matsangou M, Costa R, Carneiro B, Villaflor VM, Cristofanilli M. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget. 2017 Feb 28;8(9):16052.
2. Gao L, Wang X, Tang Y, Huang S, Hu CA, Teng Y. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. Journal of Experimental & Clinical Cancer Research. 2017 Dec;36(1):8.